STANDARD BIOTOOLS INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $85.3 | $91.0 | $106.3 | $97.9 | $130.6 |
| Operating income | -$110.2 | -$127.5 | -$76.6 | -$116.2 | -$67.5 |
| Net income | -$74.9 | -$138.9 | -$74.7 | -$190.1 | -$59.2 |
| Balance Sheet | |||||
| Total debt | — | — | $7.9 | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$82.6 | -$151.8 | -$46.1 | -$93.2 | -$57.3 |
| Share repurchases | $0.0 | $40.5 | $5.4 | $0.6 | $0.0 |
Shares outstanding 392.6M · Free float 28.7%
Annual filing data through FY ended December 31, 2025; float as of September 26, 2026.
Coverage
October 8, 2026
Small-Cap Signal
Magnolia debt falls faster after WildFire close
October 4, 2026
Weekly Deals
Micro-cap deals: Lifecore signs cash-and-CVR buyout
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Torrid Quantifies China Exit as Tariff Refund Uncertainty Spreads
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 8, 2026
Deals
Standard BioTools to Buy Treeline Biosciences in $460 Million All-Stock Deal